---
title: "$Hims & Hers Health(HIMS.US)Drug price cuts are favorable for Hims & Hers Health, which prim"
description: "$Hims & Hers Health(HIMS.US)Drug price cuts are favorable for Hims & Hers Health, which primarily deals with generic drugs. No matter how much prices drop, they can't compete with the low pric"
type: "topic"
locale: "en"
url: "https://longbridge.com/en/topics/33358072.md"
published_at: "2025-08-26T16:03:55.000Z"
author: "[空仓等暴跌](https://longbridge.com/en/profiles/19144251)"
---

# $Hims & Hers Health(HIMS.US)Drug price cuts are favorable for Hims & Hers Health, which prim

$Hims & Hers Health(HIMS.US)

Drug price cuts are favorable for Hims & Hers Health, which primarily deals with generic drugs. No matter how much prices drop, they can't compete with the low prices of generics. Moreover, Hims is not a drug manufacturer but a service provider. The lower the prices, the greater the user retention. This is actually negative for Eli Lilly and Novo Nordisk.

All-in on calls, targeting $50 $Hims & Hers Health(HIMS.US)

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md)

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.